Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Breast cancer and venous disease: a retrospective cohort study.

Serra R, Buffone G, Miglietta AM, Abonante S, Giordano V, Renne M, Lugarà M, de Franciscis S.

Ann Vasc Surg. 2013 Aug;27(6):762-6. doi: 10.1016/j.avsg.2012.10.020. Epub 2013 Jul 1.

PMID:
23809843
2.

Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy.

Giuliani S, Leonardi E, Aldovini D, Bernardi D, Pellegrini M, Soli F, Ferro A, Dalla Palma P, Decarli N, Barbareschi M.

Pathologica. 2012 Jun;104(3):93-7.

PMID:
22931039
3.

Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea.

Kim Y, Park SK, Han W, Kim DH, Hong YC, Ha EH, Ahn SH, Noh DY, Kang D, Yoo KY.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):508-15. doi: 10.1158/1055-9965.EPI-08-0133. Epub 2009 Feb 3.

4.

Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.

Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC.

Cancer Res. 1979 May;39(5):1447-54.

5.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

6.

Breast cancer in 65-year-old or older patients: clinicopathological characteristics and prognosis.

Yao L, Zhang YX, Wang LH, Zhang XY, Yan W, Pang D.

Onkologie. 2012;35(6):358-61. doi: 10.1159/000338953. Epub 2012 May 21.

PMID:
22722456
7.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
8.

Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.

Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M.

Eur J Surg Oncol. 2013 Mar;39(3):260-5. doi: 10.1016/j.ejso.2012.12.004. Epub 2013 Jan 10.

PMID:
23313014
9.

Efficacy of letrozole for advanced breast cancer in postmenopausal patients.

Ansari TN, Mahmood A, Hussain I, Samad A.

J Coll Physicians Surg Pak. 2005 Apr;15(4):204-6.

PMID:
15857590
11.

Impact of triple negative phenotype on breast cancer prognosis.

Kaplan HG, Malmgren JA.

Breast J. 2008 Sep-Oct;14(5):456-63. doi: 10.1111/j.1524-4741.2008.00622.x. Epub 2008 Jul 24.

PMID:
18657139
12.

Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer.

Lumachi F, Ermani M, Marino F, Di Cristofaro L, Tombolan V, Brunello A, Roma A, Basso U.

Anticancer Res. 2008 Jan-Feb;28(1B):491-3.

13.

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.

Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D.

Oncology. 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.

PMID:
23257904
14.

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.

Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G, Goldhirsch A.

Clin Cancer Res. 2004 Oct 1;10(19):6622-8.

15.
16.

Hormonal receptors in mammary carcinoma: comparison between quantitative and qualitative methods.

Montoro AF, Giannotti Filho O, Monteiro DM, Montoro FF, Pinho MA, Figueiredo MT.

Sao Paulo Med J. 1997 Jul-Aug;115(4):1471-4.

PMID:
9595811
17.

Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy.

Tewari M, Pradhan S, Singh U, Shukla HS.

Breast. 2007 Oct;16(5):540-5. Epub 2007 Jun 22.

PMID:
17587581
18.

Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.

Bai B, Yuan ZY, Liu DG, Teng XY, Wang SS.

Chin J Cancer. 2010 Apr;29(4):413-9.

19.

Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer.

Livi L, Meattini I, Saieva C, Franzese C, Di Cataldo V, Greto D, Franceschini D, Scotti V, Bonomo P, Nori J, Sanchez L, Vezzosi V, Bianchi S, Cataliotti L, Biti G.

Cancer. 2012 Jul 1;118(13):3236-43. doi: 10.1002/cncr.26647. Epub 2011 Oct 25.

20.

Hormone receptor status as a prognostic factor in breast cancer patients with hepatic metastases treated by liver resection.

Purnak T, Altundag K.

Ann Surg. 2007 Aug;246(2):338; author reply 338. No abstract available.

Supplemental Content

Support Center